April 22 (Reuters) - The U.S. FDA approved ImmunityBio's combination therapy to treat a type of bladder cancer, the regulator said on Monday, which would help bring the company's first product to market. (Reporting by Puyaan Singh and Pratik Jain in Bengaluru; Editing by Shailesh Kuber)
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
8.145 USD | -3.04% | +2.46% | +61.65% |
05-09 | ImmunityBio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
05-07 | ImmunityBio Shares Rise After Completion of Drug Substance Manufacturing for Cancer Treatment | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+61.65% | 5.81B | |
+7.83% | 111B | |
+11.18% | 106B | |
-12.21% | 22.24B | |
+0.44% | 21.25B | |
-4.18% | 18.97B | |
-37.85% | 18.52B | |
-8.77% | 16.81B | |
+38.51% | 12.54B | |
-24.46% | 8.09B |
- Stock Market
- Equities
- IBRX Stock
- News ImmunityBio, Inc.
- U.S. FDA approves ImmunityBio's bladder cancer therapy